COVID-19 vaccination and menstrual cycle changes: A United Kingdom (UK) retrospective case-control study

Alexandra Alvergne[1,2]*+, Gabriella Kountourides[2]*, M. Austin Argentieri[2,3], Lisa Agyen[4], Natalie Rogers[4], Dawn Knight[4], Gemma C Sharp[5,6], Jacqueline A Maybin[7], Zuzanna Olszewska[2]*

[1] ISEM, Univ Montpellier, CNRS, IRD, Montpellier, France

[2] School of Anthropology and Museum Ethnography, Oxford, UK

[3] Harvard/MGH Center on Genomics, Vulnerable Populations, and Health Disparities, Massachusetts General Hospital, Boston, USA

[4] Long Covid Support

[5] MRC Integrative Epidemiology Unit, University of Bristol, UK

[6] Bristol Medical School, Population Health Sciences, University of Bristol, UK

[7] MRC Centre for Reproductive Health, University of Edinburgh, UK

+ Corresponding author

E-mail: alexandra.alvergne@umontpellier.fr

* These authors contributed equally.

Abstract

Background. There has been increasing public concern that COVID-19 vaccines cause menstrual cycle disturbances, yet there is currently limited data to evaluate the impact of vaccination on menstrual health. Our objectives were (1) to evaluate the prevalence of menstrual changes following vaccination against COVID-19, (2) to test potential risk factors for any such changes, and (3) to identify patterns of symptoms in participants' written accounts.

Methods. We performed a secondary analysis of a retrospective online survey titled "The Covid-19 Pandemic and Women's Reproductive Health", conducted in March 2021 in the UK before widespread media attention regarding potential impacts of SARS-CoV-2 vaccination on menstruation. Participants were recruited via a Facebook ad campaign in the UK and eligibility criteria for survey completion were age greater than 18 years, having ever menstruated and currently living in the UK. In total, 26,710 people gave consent and completed the survey. For this analysis we selected 4,989 participants who were pre-menopausal and vaccinated. These participants were aged 28 to 43, predominantly from England (81%), of white background (95%) and not using hormonal contraception (58%).

Findings. Among pre-menopausal vaccinated individuals (n=4,989), 80% did not report any menstrual cycle changes up to 4 months after their first COVID-19 vaccine injection. Current use of combined oral contraceptives was associated with lower odds of reporting any changes by 48% (OR = 0.52, 95CI = [0.34 to 0.78], $P<0.001$). Odds of reporting any menstrual changes were increased by 44% for current smokers (OR = 1.16, 95CI = [1.06 to 1.26], $P<0.01$) and by more than 50% for individuals with a positive COVID status [Long Covid (OR = 1.61, 95CI = [1.28 to 2.02], $P<0.001$), acute COVID (OR = 1.54, 95CI = [1.27 to 1.86], $P<0.001$)]. The effects remain after adjusting for self-reported magnitude of menstrual cycle changes over the year preceding the survey. Written accounts report diverse symptoms; the most common words include "cramps", "late", "early", "spotting", "heavy" and "irregular", with a low level of clustering among them.

Conclusions. Following vaccination for COVID-19, menstrual disturbance occurred in 20% of individuals in a UK sample. Out of 33 variables investigated, smoking and a previous history of SARS-CoV-2 infection were found to be risk factors while using oestradiol-containing contraceptives was found to be a protective factor. Diverse experiences were reported, from menstrual bleeding cessation to heavy menstrual bleeding.

Introduction

There has been increasing public concern that COVID-19 vaccines cause disruption of menstrual cycles [1–3], leading to problematic menstrual symptoms, vaccine hesitancy [4] and fears about the impact of vaccination on fertility [5–7]. There are currently limited data [8] for investigating the relationship between the COVID-19 vaccines and menstrual cycles [1,9,10]. This is despite rising awareness among clinicians that the menstrual cycle should be used as a vital sign of female health [11,12], that sex is a biological variable which should be considered in immunological studies [13] and that there have been reports of heavy, infrequent or irregular menstrual bleeding following vaccination [1,8–10]. Quantitative evidence for any such relationship between COVID-19 vaccination and menstrual cycle disturbance, as well as the factors mediating this relationship, are crucial for evaluating how female health has been impacted by the pandemic.

The first published study on the topic of vaccine effects on menstrual cycles dates back to 1913, when a medical doctor at the Presbyterian Hospital, New York, concluded that there was a striking relationship between the prophylactic typhoid vaccine and menstrual disturbances among one hundred cases [14]. After ruling out all other apparent causes, he found that 53% showed some type of disturbance, including increased or decreased frequency, increased or decreased volume and dysmenorrhoea [14]. These disturbances disappeared within 6 months of the vaccine, suggesting that any such vaccine side-effect was temporary. There has also been a report of menstrual disturbances following inoculation with the hepatitis vaccine in a Japanese study conducted in 1982. Among 16 hospital employees, 7 reported various menstrual abnormalities including decreased volume of menstruation, infrequent or too frequent menses

[15]. The changes were attributed to the use of human plasma to make the vaccine (antigens were derived from human plasma, containing hormonal impurities). More recently, large-scale studies on the effects of vaccination on menstrual disturbances reported mixed results. A 2018 study of 29,846 female residents of Nagoya City, Japan, found that none of the 24 symptoms investigated, including menstrual symptoms, were associated with increased odds of occurring after administration of the HPV vaccine. However, age-adjusted odds of hospital visits were increased for "abnormal amount of menstrual bleeding" (OR=1.43, 95%CI=[1.13 to 1.82]), "irregular menstruation" (OR=1.29, 95%CI=[1.12 to 1.49]) and chronic, persisting "abnormal amount of menstrual bleeding" (OR 1.41, 95% CI: 1.11–1.79)[16]. Although retrospective and sensitive to recall bias among those receiving the vaccine, the study suggests a possible link between the HPV vaccine and menstrual irregularities. Another study applying a signal detection analysis on the FDA Vaccine Adverse Event Reporting System (VAERS) shows a disproportionate number of reports of premature ovarian insufficiency, amenorrhea, irregular menstruation, increase in FSH and premature menopause following administration of the HPV vaccine [17]. However, the evidence is non-causal, and relationships might depend on the type of vaccine. With regards to COVID-19, the UK's Medicine and Healthcare products Regulatory Agency (MHRA) is closely monitoring reports of menstrual disorders [18], with more than 30,000 reports made to its yellow card surveillance scheme by 2 September 2021 for both mRNA and adenovirus-vectored COVID-19 vaccines [19]. Recent data from a gender-diverse sample receiving COVID-19 vaccination in the US suggests that changes in the form of heavy and breakthrough bleeding affect many people. However, there has been no quantitative assessment of the risk factors for menstrual disturbances following COVID-19 vaccination prior to widespread media attention ([8], Box 1).

Objectives of the study

The objectives of this study are three-fold: (1) to evaluate the incidence of reports of menstrual changes of any kind following COVID-19 vaccination in a sample broadly representative of those who menstruate in the UK, (2) to investigate the risk factors for reporting any menstrual changes following COVID-19 vaccination, and (3) to capture the types and breadth of menstrual disturbances by analysing the text written by participants. We build on a large retrospective cross-sectional study on menstruation during the pandemic conducted in the UK, launched before UK media coverage of concerns over menstrual vaccine side-effects and including both quantitative and textual data on menstrual cycle changes perceived to be induced by the COVID-19 vaccines.

Methods

Study design

The online survey was initially designed to evaluate whether and how the COVID-19 pandemic influenced menstrual health. Retrospective and self-reported data on menstrual cycles, behaviour, life circumstances and health before and during the pandemic as well as SARS-CoV-2 infection and vaccination status were collected using an online survey hosted on the Qualtrics platform (www.qualtrics.com). All survey responses were anonymized using randomly generated IDs. The study, titled "The Covid-19 Pandemic and Women's Reproductive Health" has been reviewed by, and received ethics clearance through, the Oxford University School of Anthropology and Museum Ethnography Departmental Research Ethics Committee [SAME_C1A_20_029].

Patient and Public Involvement

During the design of survey questions, input from a panel of women suffering from Long Covid, referred to us by the Long Covid Support online group (https://www.longcovid.org/), was incorporated. The results were discussed with panel members who were also invited to co-author the paper and co-design dissemination plans.

Study population

The online survey was launched on March 8, 2021. The title of the survey was kept general ("female reproductive health and the COVID pandemic") so as not to oversample individuals with specific interest in menstrual cycles and COVID infection or vaccination. The survey was disseminated through a Facebook advertising campaign, and included images of women of diverse ethnicities, ages, and abilities, as well as images of breastfeeding and pregnant women (SI1); we fine-tuned the ad targeting (to the extent that Facebook allows) throughout the campaign to ensure even geographical and socio-economic spread. As explained in the information page (SI2), participants could only complete the survey if they were over 18, had ever menstruated, currently lived in the UK, and gave informed consent to the use of their data. The survey included a maximum of 105 questions depending on individual circumstances (SI3) and took an average of 24 minutes to complete. Of the eligible participants who started the survey, 61% answered all questions after giving their consent (on average participants completed 80% of the questionnaire). In case of survey fatigue, progress could be saved for up to 14 days to allow participants to resume later. The survey was disseminated through a Facebook advertisement campaign targeting all menstruators in the UK, from 08/03/21 to 01/06/21, at which point there had been no new entries for a week. During the campaign, we used a stratified sampling strategy to ensure that subgroups of the UK population in terms of

164 age, income and ethnicity were represented in the final sample. In total, 695,543 people viewed

165 the survey ad on their Facebook page and 26,710 with eligible criteria gave consent and

166 completed it (there were no duplicates), leading to a 3.8% response rate. The data, data

167 dictionary and scripts are available on the Open Science Framework Platform

168 (https://osf.io/pqxy2/).

Outcome: vaccine side-effects on menstrual cycles

While the survey did not initially aim to evaluate the impact of vaccination on menstrual cycles

specifically, a question was included to assess participants' perception of their menstrual cycles

following vaccination at the end of the survey. Specifically, participants who indicated that they

had been menstruating in the past 12 months, received 1 or 2 doses of the COVID-19 vaccines

and were not involved in a clinical trial were asked "*Have you noticed any changes to your*

menstrual cycles since you got vaccinated?", to which 1 of 4 possible answers could be given:

"No", "Yes, my menstrual cycles are MORE disrupted", "Yes, my menstrual cycles are LESS

disrupted", "Other (please state)". Although "disruption" per se was not defined, by the time

participants answered this question, they had already completed many questions on menstrual

cycle regularity, duration, and symptoms. At the time of the survey design, anecdotal reports of

menstrual effects of the vaccine were only just beginning to circulate, while people with Long

Covid were reporting either improvement or worsening of their symptoms in general after

vaccination. This question was included with the intention of investigating the latter effects.

Participants could select the answer "Other", which in some cases may not have been a different

decision from choosing either "more disrupted" or "less disrupted". For analysis, we thus

transformed these variables to represent a binary outcome ("No changes" vs. "Any other

changes").

Exposures

A total of 33 variables were extracted for this analysis. In addition to socio-demographic variables (age, income, education, gender, ethnic group, marital status), and standard proxies for health (BMI, smoking status, physical activity, regular use of vitamins/supplements, regular use of medicine), the dataset included vaccine-related, COVID and pandemic-related, and reproductive variables (See SI4 for the operationalization of variables). First, data on the type of vaccine received, of which only two had been approved for use in the UK at the time (Pfizer BioNTech/Oxford-AstraZeneca/Not sure), and the timing of the first vaccination (month/year) were included. Second, COVID status was operationalized in two ways: (i) based on whether people thought they had had COVID, as widespread testing had not been available in the UK in the early months of the pandemic which fell within the survey period, leading to three categories: *No COVID*, *acute COVID* (symptoms lasting less than 28 days) and *Long Covid* (symptoms lasting more than 28 days) as well as (ii) based on a combination of testing and self-diagnosis, leading to three categories: *No COVID* (no tests or negative tests), *COVID tested +* (positive test) and "*Self-diagnosed positive*" (referring to individuals who had a suspected or clinically diagnosed COVID infection but had not obtained positive PCR, antigen or antibody tests). We included this last category due to the unavailability of widespread testing in the UK in the first wave of the pandemic in 2020 and ongoing questions about the accuracy and optimal timing of antigen and antibody tests. In addition, variables indicative of changes in both life satisfaction and menstrual cycle symptoms compared to before the pandemic were also included to adjust for changes experienced because of the pandemic and/or the infection rather than vaccination. Third, reproductive variables indicative of menstrual health before the pandemic

(age at menarche, cycle length, period length, cycle irregularity, heavy bleeding), reproductive

history (number of deliveries) and contraceptive use were included.

Statistical analysis

The aim of the quantitative analysis was two-fold: (1) to quantify the extent to which individuals

answered "No changes" when asked about any perceived changes to their menstrual cycle

following COVID-19 vaccination, and (2) to evaluate potential risk and protective factors for

selecting any other answer. The original outcome variable is nominal (two or more categories

with no intrinsic order) but violates the IIA assumption (Independence or Irrelevant

Alternatives) as options were not independent, thus we dichotomized the variable into two

mutually exclusive categories ("No changes", "Any other changes") and performed logistic

regressions. We first conducted a series of exploratory univariable analyses, investigating each

of 33 variables as potential risk factors for reporting changes in menstrual cycles following

vaccination. We then retained all variables significant at the false discovery rate (FDR)

threshold (FDR-corrected $P<0.05$) [20] for consideration in multivariable analyses. We then

conducted separate multivariable analyses with each of the variables identified in the

univariable analyses as exposures variables. Each multivariable model was adjusted for

potential confounders, which were defined as variables significant at the FDR threshold in the

univariable analyses and with a potential confounding (but not mediating) effect according to

hypothesized directed acyclic graphs (DAG, SI5). Estimates and confidence intervals on the

log-odds scale were converted to odds-ratios for reporting. To test the significance of individual

coefficients, p-values were derived from Wald χ^2 statistics. For all models, we plotted a receiver

operating characteristic curve (ROC) and computed a measure of the accuracy of the chosen

model in predicting the outcome using the area under the curve (AUC). As an alternative way

of selecting covariates for the multivariable models, and to improve model prediction accuracy,

we also performed LASSO regression using the "*glmnet*" package in R [21]. As the range and

scale of variables can influence the penalization for having too many variables in elastic net

models, all ordinal variables were coded numerically and re-classed as continuous, and all

continuous variables were centered and standardized. Nominal categorical variables were

broken out into individual binary dummy variables for all response levels except for the

reference level.

Missing data

The analysis of complete cases only can introduce bias and lead to a substantial reduction of

statistical power [22], especially if it is plausible that the data are missing at random or not

completely at random. An evaluation of the missing data suggested that multiple imputation

was advisable (SI6). The average proportion of missing values across all variables in the dataset

was 3.8%, which was mostly accounted for by the variable BMI (38% of missing data, SI6). To

handle missing data, we used a multiple imputation approach using the R package '*missRanger*'

[23], which combines random forest imputation with predictive mean matching [23]. Prior to

all analyses, we imputed 5 datasets, with a maximum of 10 iterations specified for each

imputation. Each imputation was also weighted by the degree of missing data for each

participant, such that the contribution of data from participants with higher proportions of

missingness was weighted down in the imputation. We set the maximum number of trees for

the random forest to 200 but left all other random forest hyperparameters at their default. The

average out-of-bag (OOB) error rate for multiple imputation across all imputed datasets was

0.08 in women (range: 0 to 0.77) and 0.08 in men (range: 0 to 0.69). Parameter estimates for

all five datasets were pooled to provide more accurate estimates. A sensitivity analysis was also

performed on the complete cases without missing data imputation (n=1,548 (SI7)).

260
Text analysis

We first built a custom text cleaning function using the *'textclean'* [24] and *'tidytext'* [25] R

packages to analyse the text written by participants selecting the "Other" category in the

outcome variable (n=574). The resulting corpus was tokenized (broken into individual units)

and lemmatized (words derived from others, such as "vaccine" and "vaccination" were grouped

by their stem version "vaccine" (SI8). The corpus was analysed to answer the following 3

questions: (i) which single words (unigrams) and pairs of adjacent words (bigrams) are most

frequent? (ii) which words co-occur in the same sentence? (iii) Are there clusters of symptoms?

To investigate the commonality of words, we explored the frequency of unigrams and bigrams

within all responses. We performed a correlation analysis on the most important words for

menstrual cycle descriptions to measure the association between words using the correlation

index (phi coefficient (φ)). To explore patterns of symptoms we examined the words that

commonly occur together (though not necessarily adjacent) to visualize groups of words that

cluster together. Clusters were visualized by arranging correlated words into a combination of

connected nodes (network graph) using the *'igraph'* package [26].

Results

278
279
Out of the 26,710 individuals who completed the survey, 8,539 (32%) reported having been

vaccinated, with either 1 (n=7,270) or 2 doses (n=1,269). In the final sample, we only included

individuals living in the UK who knew about their vaccination status, who had a period in the

last 12 months and who were also pre-menopausal and not pregnant. We also excluded

participants who selected "Other changes" and contributed text to the effect of "too early to

say" when describing menstrual disturbances following COVID-19 vaccination (n=369, 64%

of those selecting the answer "Other changes)" (Fig. 1)

288
289
290
291
292   **Figure 1. Flowchart of the study population selection**
293
The final sample size of vaccinated individuals is 4,989, of which 53% received the Oxford-

AstraZeneca and 47% the Pfizer BioNTech vaccine (Table 1). The median age is 35 (IQR: 28

to 43) years old, with most participants living in England (81%), self-reporting as white (95%)

and self-identifying as women (99%). We then grouped categories for the variables gender

(women vs. other) and ethnic group (white vs. other). Although the UK vaccination campaign

targeted older and at-risk populations to begin with, there does not seem to be an over-

representation of over 40-year-olds. Note that 54% of participants had no deliveries and 49%

had a university or college degree.

Characteristic	N = 4,989
Age, Median (IQR)	35 (28 – 43)
Education level, n (%)	
Higher or secondary or further education (A-levels, BTEC, Baccalaureate)	851 (17)
Primary & Secondary	303 (6.2)
Post-graduate degree	1,324 (27)
College or University	2,395 (49)
Unknown	116
Place of residence, n (%)	
UK-England	4,031 (81)
UK-Northern Ireland	159 (3.2)
UK-Scotland	542 (11)
UK-Wales	257 (5.2)
Ethnic group, n (%)	
White	4,734 (95)
Asian	113 (2.3)
Black	21 (0.4)
Mixed	101 (2.0)
Other	18 (0.4)
Unknown	2
Net income before pandemic, n (%)	
Between £13,682 and £22,140	656 (15)
Between £22,140 and £29,254	614 (14)
Between £29,254 and £39,397	795 (18)
Between £39,397 and £76,144	1,453 (33)
Less than £13,682	430 (9.8)
More than £76,144	427 (9.8)
Unknown	614
Smoking status before pandemic, n (%)	
I have never smoked	3,327 (67)
No, but I have smoked in the past	1,157 (23)
Yes, I usually smoked fewer than 10 cigarettes/day	334 (6.7)
Yes, I usually smoked more than 10 cigarettes/day	170 (3.4)
Unknown	1
Marital status, n (%)	
Separated	348 (7.2)
Married/partnered	2,033 (42)
Nevermarried/partnered	2,449 (50)
Widowed	27 (0.6)
Unknown	132
Gender, n (%)	
Man	1 (<0.1)
Non Binary	24 (0.5)
Other (please state)	22 (0.4)
Woman	4,939 (99)
Unknown	3
Number of deliveries, n (%)	
0	2,694 (54)
1	693 (14)
2	1,017 (20)
3+	584 (12)
Unknown	1
Contraceptive use at the time of the survey, n (%)	
Combined estradiol-progestin	441 (11)
Copper IUD	225 (5.4)
None	2,421 (58)
Other	84 (2.0)
Progestin only	854 (21)
Sterilization	130 (3.1)
Unknown	834
COVID status (type), n (%)	
COVID -	3,377 (75)
Long COVID	462 (10)
Short COVID	687 (15)
Unknown	463
COVID status (diagnosis), n (%)	

Characteristic	N = 4,989
Negative	3,377 (76)
Self diagnosed +	395 (8.9)
Tested +	671 (15)
Unknown	546
Number of vaccination shots, n (%)	
Yes, one shot	4,096 (82)
Yes, two shots	893 (18)
Vaccine type, n (%)	
Oxford-AstraZeneca	2,600 (53)
Pfizer-BioNTech	2,335 (47)
Unknown	54
Timing of 1st dose, n (%)	
Before 2021	331 (6.7)
February 2021	1,469 (30)
January 2021	1,497 (30)
March 2021	1,659 (33)
Unknown	33

303 **Table 1.** Summary of the sample characteristics

304
305

Risk factors for COVID-19 vaccine-related changes in menstrual cycles

Most individuals reported no changes to their menstrual cycles following COVID-19

vaccination (80%). Only 6.1% reported more disruption, 1.5% reported less disruption and

11.5% reported "Other changes", which, based on the previous questions participants were

exposed to, could be interpreted as any changes in cycle length and regularity, period duration

and volume of menstrual bleeding as well as premenstrual symptoms.

The univariable analyses show that the odds of reporting any changes to menstrual cycles after

COVID-19 vaccination is associated with contraceptive type, smoking behaviour, COVID

status and menstrual cycle changes over the last year (Fig. 2). All univariable models offered

poor discriminative utility (AUC below 0.65, SI9). There were no differences associated with

age, body mass index, ethnic group, gender, marital status, physical activity, income, education,

place of residence, cycle length, period length, irregular cycles, heavy bleeding, vaccine type,

vaccine timing, parity, life satisfaction changes, medication use, use of vitamins/supplements,

endometriosis, PCOS, thyroid disease, uterine polyps, uterine fibroids, inter cystitis and eating

disorders (Fig. 2; SI10).

Figure 2. Outputs of univariable models for the odds of reporting any menstrual cycle changes following COVID-19 vaccination. The figure depicts odds-ratio and 99%CI for 33 variables. **: FDR P-value < 0.01; *** FDR P-value < 0.001.

The multivariable analyses show that the usage of combined oral contraceptives is associated with lower odds of reporting any changes by 48% (OR=0.52, 95CI=[0.34 to 0.78], *P*<0.001) while the odds of reporting any changes is increased by 44% (OR=1.44, 95CI=[1.07 to 1.94] for current smokers, *P*<0.01) and by 49 to 70% for individuals with a positive COVID status

[Long Covid (OR=1.61, 95CI=[1.28 to 2.02], *P*<0.001), acute COVID (OR=1.54; 95CI=[1.27

to 1.86], *P*<0.001); self-diagnosed positive (OR=1.70, 95CI=[1.34 to 2.16], *P*<0.001), tested

positive (OR=1.49, 95CI=[1.20 to 1.84], *P*<0.01), Figs 3 & 4, SI11]. The effects remain after

adjusting for self-reported overall magnitude of menstrual cycle changes over the year

preceding the interview (pandemic-related changes in menstrual cycle (PRCM)), which is

positively associated with the risk of reporting any changes (OR=1.16, 95CI=[1.06 to 1.26],

P<0.01). The findings were replicated when using complete cases data (SI7), indicating that the

results are not an artefact of the missing data imputation process.

340
Figure 3. Outputs of multivariable models for the odds of reporting any menstrual cycle changes

following COVID-19 vaccination. Each of the 5 exposures associated with the outcome at FDR-

adjusted *P*<0.05 in the univariable analysis (i.e., pandemic-related menstrual changes (PRMC),

contraceptive use, COVID-19 type, COVID-19 diagnosis, smoking behaviour) was entered in a

multivariable model together with potential confounding (but not mediating) effects where appropriate

(see SI5 for DAGs). *Model I*: Smoking behaviour; *Model II*: Contraceptive use; *Model III*: COVID-19

type adjusted for contraceptive use and smoking behaviour; *Model IV*: COVID-19 diagnosis adjusted

for contraceptive use and smoking behaviour; *Model V*: PRMC adjusted for COVID-19 type; *Model VI*:

PRMC adjusted for COVID-19 diagnosis.

350
351

352
353
Figure 4. Predicted probability of reporting any menstrual changes following COVID-19

vaccination. Predicted values and 95 confidence intervals given contraceptive use, COVID status

(based on type and certainty of diagnosis) and menstrual cycle changes over the last year. Most

individuals (80%) reported no menstrual disturbances following COVID-19 vaccination. This

probability was lower for users of combined (including oestradiol) contraceptives and higher for current

smokers and those who had had a positive COVID status.

360
The type of contraceptive used and the history of COVID infection, while correlated, did not

offer good predictive value for whether an individual will report changes to their menstrual

cycle. Each exposure alone contributed an increase of only 1 to 3% of explained variance. The

AUCs for the multivariate models were low across the imputed datasets (0.57 to 0.61) and the

complete case dataset (0.63): the variables considered are not sufficient for predicting

accurately whether an individual will report menstrual changes after vaccination. To improve

the prediction accuracy of our models, we also performed a LASSO regression considering all

33 variables, but no improvement in AUC was obtained (SI12), suggesting that key variables

are missing from our dataset and/or that the subjective outcome is not defined specifically

enough for accurate prediction, especially if experiences of menstrual changes are diverse.

Description of menstrual cycle changes following COVID-19 vaccination

Most common changes reported. The analysis of text written by participants who selected

"Other changes" (n= 574, 57% of those reporting any changes) rather than "MORE disruption"

or "LESS disruption" showed concerns over cycle length and menstrual bleeding patterns. The

most common unigrams (individual words) were "late", "bleed", "early", "long", "heavy",

"spotting", "short", "pain" and "stop" and the most common bigrams (pairs of adjacent words)

were "day late", "period start", "heavy bleed", and "late period" (Fig. 5). While many reported

menstrual cycle changes that entailed heavier bleeding/period, there was no one single pattern

of symptoms, with changes including both early and late period, and diverse experiences

reported (from "miss period" to "heavy bleed").

 Figure 5. Most common words used to describe menstrual cycle changes following COVID-19

vaccination (n = 574). (A) Most common words. (B) Most common pairs of adjacent words.

Associations between symptoms. Only a few symptoms are correlated ($\varphi < -0.2$ or $\varphi > 0.2$). "Cramps" positively correlate with "pain" and "heavy" and "bleed" negatively correlates with "late". Further, "lighter" positively correlates with "normal", as participants report that "*period was two days late, and lighter than normal*". However, "lighter" and "late" do not co-occur more than expected by chance (Fig. 6).

Figure 6. Correlation matrix between key words within sentences describing menstrual cycle changes following COVID-19 vaccination. The size and colour of the dots indicates the strength of the correlation (phi coefficient) between words.

Clusters of words. Different clusters of symptoms emerge from the text, such as irregular periods, heavy cramps, and pain. However, the "pain" cluster encompassed many words that are weakly correlated, suggesting a diversity of pain experience. There was also some uncertainty regarding which changes do occur, with participants finding it "*hard to say if the*

404   *irregular periods are still due to covid or the vaccination*". When only correlations >0.20 were

405   considered (Fig. 7), 4 clusters emerged: "heavy, painful, cramps", "irregular, disruption", "lot,

406   clot", and an experiential cluster "symptom, experience, pain, increase, feel". Notably, various

407   pain experiences that do not directly relate to menstrual cramps were reported in the main text,

408   including stomach pain and headache.

411
412 **Figure 7. Network of words describing menstrual cycle changes following vaccination with**

413   **COVID-19.** Words have been lemmatised to the root of their words, for example "light" can represent

414   both "lighter" and "light. Node size represents degree centrality (the commonality of words, only words

415   with more than 5 occurrences are included). Edge thickness is a measure of correlation between words.

Discussion

Using data collected in the UK prior to widespread media attention to menstrual disturbances following COVID-19 vaccination, this study found that among pre-menopausal vaccinated individuals who menstruated in the 12 months preceding the survey, 20% reported any changes to their menstrual cycles up to 4 months after receiving their first injection. In this sample, there was an association between a history of COVID infection and an increased relative risk of reporting changes of menstrual cycles following vaccination against COVID-19, independently of how COVID status was determined, i.e., using COVID type (Acute vs. Long Covid) or certainty of diagnosis (tested vs. self-diagnosed positive). This study also found that using contraceptives containing oestradiol (e.g., the pill, the vaginal ring, and the patch) is associated with a 50% lower odds of reporting menstrual cycle changes post-COVID-19 vaccination. Beyond smoking, none of the other variables investigated including age, BMI, socio-economic status, or vaccine type were associated with post-vaccination menstrual disturbances. Descriptive accounts point to diverse menstrual disturbances including "late" and "early" periods as well as "heavy bleeding" (Box 1).

Meaning of the study: Most menstruating people in our sample did not experience menstrual changes following COVID-19 vaccination. This provides reassuring data when counselling reproductive-aged women about COVID-19 vaccination and menstrual changes. However, one in five did report menstrual disturbance following COVID-19 vaccination, a proportion that is above the threshold for a "very common" adverse reaction according to international pharmacovigilance standards. Clinicians should consider counselling women about these possible menstrual effects following COVID-19 vaccination, while emphasising the need to

seek medical advice if they are severe, last more than one cycle or involve "red flag" symptoms

such as inter-menstrual bleeding, post-coital bleeding, or post-menopausal bleeding. This study

also suggests that current smoking and having had COVID-19 may make one more likely to

experience menstrual disturbance following COVID-19 vaccination and that those on the

COCP are less likely to experience menstrual disturbance. Knowledge of risk factors may help

tailor advice to individuals who menstruate prior to COVID-19 vaccination.

Strengths and weaknesses of the study: The analysis is drawing upon a survey not specifically

designed to investigate the impact of COVID-19 vaccination on menstruation. It is retrospective

in nature as well as sensitive to selection, recall and report biases and does not systematically

assess the full spectrum of menstrual disturbance defined by the International Federation of

Gynecology and Obstetrics Abnormal Uterine Bleeding System 1 [27]. We took several steps

to limit selection bias during sampling (see methods) and the initial survey is broadly

representative of people infected with COVID (8.9% with a positive PCR test compared to a

national proportion of 6.6% at the time [28]). However, approximately 45% of the sample had

received at least one dose of the vaccine, as compared to the national proportion of 59% by the

time of the last survey entry [29]. In addition, menstrual changes may manifest later, and our

study does not have the time depth to evaluate this possibility. However, among the studies of

other vaccines conducted on a longer timescale, no effect was found by 6-9 months [14,30].

Strengths and weaknesses of the study in relation to other studies: While the survey is also

sensitive to *recall* bias, it is limited as compared to more recent surveys [8] as the issue of

menstrual disturbances was not reported by the British Broadcasting Corporation until May 13,

2021 [31], as compared to a flurry of attention in US media throughout April [1–3].

Reassuringly, reporting bias would be expected to affect all sections of the sample similarly,

and thus it would not explain specific associations such as with contraceptive type.

Unanswered questions and future research: The association between a history of SARS-

CoV-2 infection and menstrual disturbances post-vaccination in this study may be partly due to

the effect of prior infection with SARS-CoV-2 on the immune response to vaccination, which

has been found to be heightened [32]. Biological data would be needed to verify this hypothesis.

The findings also suggest that exogenous oestrogen may reduce post-vaccination menstrual

disturbances through anti-inflammatory or anti-viral effects. This is consistent with the recent

suggestion that an "inflammatory" rather than an "ovulatory" route might explain menstrual

disturbances following COVID-19 vaccination given the high prevalence of breakthrough

bleeding among users of long-acting reversible contraceptives (LARC) [8]. A protective effect

of oestrogen [33]. and oestradiol [34] has been suggested in relation to the severity of COVID-

19, and randomized control trials on unbiased samples would be needed to establish causality

between oestrogen and the reduced risk of menstrual disturbances following COVID-19

vaccination. Finally, the diversity of menstrual responses to COVID-19 vaccination might be

partly explained by the timing of vaccination in relation to the menstrual cycle. The findings

thus call for routine menstrual data collection in COVID-19 and vaccination studies as well as

research into the mechanisms of menstrual disturbance following vaccination.

487
488

489
490
491
492

References

493
494

References

1.   McShane J. Can the vaccine make your period worse? These women say yes. The Lily.

2021.

2.   Saar T. Women Say COVID Vaccine Side Effects Impact Their Periods, So Why Don't

Doctors Care? Haaretz.

3.   Efrati I. Some Vaccinated Israeli Women Report Irregular Menstrual Cycles, Bleeding.

Haaretz. 2012.

4.   Butler K. Social Media Influencers Are Spreading Wild Rumors About COVID-19

Vaccines and Periods. In: motherjones.com [Internet]. Available:

https://www.motherjones.com/politics/2021/04/social-media-influencers-are-

spreading-wild-rumors-about-covid-19-vaccines-and-periods/

5.   Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et

al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N

Engl J Med. 2021;384: 2273–2282. doi:10.1056/NEJMoa2104983

6.   Joi P. Do COVID-19 vaccines affect menstruation and fertility? In: Gavi, the Vaccine

Alliance [Internet]. 2021. Available: https://www.gavi.org/vaccineswork/do-covid-19-

vaccines-affect-menstruation-and-fertility

7.   Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy.

Obstet Gynecol. 2021;Publish Ah. doi:10.1097/AOG.0000000000004457

8.   Lee KMN, Junkins EJ, Fatima UA, Cox ML, Clancy KBH. Characterizing menstrual

bleeding changes occurring after SARS-CoV-2 vaccination. medRxiv. 2021;

2021.10.11.21264863. doi:10.1101/2021.10.11.21264863

9.   Gunter J. The COVID-19 vaccine and menstrual irregularities. In: The Vajenda

519   [Internet]. 2021. Available: https://vajenda.substack.com/p/the-covid-19-vaccine-and-

520   menstrual

521   10.   Sharp G, Fraser A, Sawyer G, Kountourides G, Easey K, Ford G, et al. The COVID-19

522   pandemic and the menstrual cycle: research gaps and opportunities. Int J Epidemiol.

523   2021;In press. doi:10.31219/osf.io/fxygt

524   11.   ACOG Committee Opinion No. 651: Menstruation in Girls and Adolescents: Using the

525   Menstrual Cycle as a Vital Sign. Obstet Gynecol. 2015;126: e143-6.

526   12.   Li K, Urteaga I, Wiggins CH, Druet A, Shea A, Vitzthum VJ, et al. Characterizing

527   physiological and symptomatic variation in menstrual cycles using self-tracked mobile-

528   health data. npj Digit Med. 2020;3: 79. doi:10.1038/s41746-020-0269-8

529   13.   Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol.

530   2016;16: 626–638. doi:10.1038/nri.2016.90

531   14.   Lamb AR. Experiences with prophylactic Typhoid vaccination. Arch Intern Med.

532   1913;XII: 565. doi:10.1001/archinte.1913.00070050082008

533   15.   Shingu T, Uchida T, Nishi M, Hayashida K, Kashiwagi S, Hayashi J, et al. Menstrual

534   Abnormalities after Hepatitis B Vaccine. Kurume Med J. 1982;29: 123–125.

535   16.   Suzuki S, Hosono A. No association between HPV vaccine and reported post-

536   vaccination symptoms in Japanese young women: Results of the Nagoya study.

537   Papillomavirus Res. 2018. doi:10.1016/j.pvr.2018.02.002

538   17.   Gong L, Ji H-H, Tang X-W, Pan L-Y, Chen X, Jia Y-T. Human papillomavirus

539   vaccine-associated premature ovarian insufficiency and related adverse events: data

540   mining of Vaccine Adverse event Reporting System. 123AD. doi:10.1038/s41598-020-

541   67668-1

542   18.   Products M& H, Agency R. Coronavirus vaccine - weekly summary of Yellow Card

543   reporting (1st July 2021). 2021. Available:

544   https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-

545   reactions/coronavirus-vaccine-summary-of-yellow-card-reporting

546   19.   Male V. Menstrual changes after covid-19 vaccination. BMJ. 2021; n2211.

547   doi:10.1136/bmj.n2211

548   20.   Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and

549   Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995. doi:10.1111/j.2517-

550   6161.1995.tb02031.x

551   21.   Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models

552   via coordinate descent. J Stat Softw. 2010. doi:10.18637/jss.v033.i01

553   22.   Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple

554   imputation for missing data in epidemiological and clinical research: potential and

555   pitfalls. BMJ. 2009;338: b2393–b2393. doi:10.1136/bmj.b2393

556   23.   Mayer M. missRanger: Fast Imputation of Missing Values.

557   24.   Rinker TW. textclean: Text Cleaning Tools version 0.9.3. Buffalo, New York; 2018.

558   Available: https://github.com/trinker/textclean

559   25.   Silge J, Robinson D. tidytext: Text Mining and Analysis Using Tidy Data Principles in

560   R. J Open Source Softw. 2016;1: 37. doi:10.21105/joss.00037

561   26.   Csardi G, Nepusz T. The Igraph Software Package for Complex Network Research.

562   InterJournal, Complex Syst. 2006;1695: 38.

563   27.   Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and

564   abnormal uterine bleeding symptoms and classification of causes of abnormal uterine

565   bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143:

393–408. doi:10.1002/ijgo.12666

28.   Government U. Coronavirus Cases in the United Kingdom. Available:

https://coronavirus.data.gov.uk/details/cases

29.   UK Health Security Agency. Coronavirus (COVID-19) in the UK: Vaccinations in

United Kingdom. Available: https://coronavirus.data.gov.uk/details/vaccinations

30.   Shahani S, Patel KL, Merchant P. Evaluation of endocrine parameters in clinical trials

with β-hCG vaccine. Contraception. 1991;43: 67–75. doi:10.1016/0010-

7824(91)90127-2

31.   Robinson O, Schraer R. Covid vaccine: Period changes could be a short-term side

effect. BBC. 2021. Available: https://www.bbc.com/news/health-56901353

32.   Kelsen SG, Braverman AS, Patel P, Aksoy MO, Hayman J, Rajput C, et al. Heightened

COVID-19 Vaccine Response Following SARS-CoV-2 Infection. medRxiv. 2021;

2021.03.18.21253845. doi:10.1101/2021.03.18.21253845

33.   Haitao T, Vermunt J V., Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, et

al. COVID-19 and Sex Differences. Mayo Clin Proc. 2020;95: 2189–2203.

doi:10.1016/j.mayocp.2020.07.024

34.   Costeira R, Lee KA, Murray B, Christiansen C, Castillo-Fernandez J, Lochlainn MN,

et al. Estrogen and COVID-19 symptoms: Associations in women from the COVID

Symptom Study. PLoS One. 2021. doi:10.1371/journal.pone.0257051

Box 1

What is already known on this topic?

- Menstrual disturbances including changes in frequency and/or dysmenorrhoea following vaccination have been reported as early as 1913 for the typhoid vaccine (1). Since then there have only been a few studies investigating this topic, using small sample sizes (hepatitis vaccine (2)) or reporting mixed results (HPV vaccine (3,4)).

- The UK's Medicine and Healthcare products Regulatory Agency (MHRA) is closely monitoring reports of menstrual disorders, with more than 30,000 reports made to its yellow card surveillance scheme by 2 September 2021 following vaccination with both mRNA and adenovirus-vectored COVID-19 vaccines (5).

- In a recent preprint of a retrospective case-control study of 21,380 pre-menopausal participants living in the US, 45.8% of 9,579 people with regular menstrual cycles experienced heavier bleeding after COVID-19 vaccination. In addition, 70.5% of 1,545 non-menstruating people using long-acting reversible contraceptives (LARC) experienced breakthrough bleeding after COVID-19 vaccination (6). This informative study may be affected by selection bias and may not be generalisable.

What this study adds

- In a large sample of participants vaccinated against COVID-19 surveyed in the UK before widespread media attention to related menstrual changes, the prevalence of menstrual changes was 1 in 5.

- Out of 33 socio-demographic, health, vaccine, COVID- and pandemic-related and reproductive variables, the odds of reporting any menstrual changes following COVID-

19 vaccination were associated with a history of SARS-CoV-2 infection, smoking

behaviour and the type of contraceptives used.

• Menstrual changes that were reported were diverse, ranging from increased bleeding to

the cessation of bleeding.

• The study highlights the need for greater consideration of the menstrual cycle in health

interventions.

616
617

Supporting Information Caption

SI1: Recruitment facebook ads

SI2 : Information sheet

SI3 : Survey questions

SI4 : Operationalization of variables

SI5 : DAG

SI6: Missing data evaluation

SI7: Complete cases analysis

SI8 : Text analysis

SI9 : AUC univariable models

SI10: Table univariable models

SI11 : Table multivariable models

SI12: AUC Lasso